Pistoia Research Alliance Adds and Loses Members, Keeps Protections
Published Date: 7/22/2026
Notice
Summary
The Pistoia Alliance, a group working together on research, just added six new members from the US, Canada, the UK, the Netherlands, and an individual from Massachusetts. One member from Germany left the group. These changes keep the group’s special legal protections in place, and membership is still open for others who want to join.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18136, United States v. KKR & Co. Inc., et al.; Proposed Final Judgment and Competitive Impact Statement
2026-16850, United States of America, et al. v. CRH PLC, et al. Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Tennessee are stopping APAC-Tennessee from buying Standard Construction Group because it could hurt competition. To fix this, both companies must sell two key facilities in Memphis and Millington, Tennessee. People have 60 days to share their thoughts before the deal is finalized, keeping the market fair and open.
2026-16112, United States et al. v. Cal-Maine Foods, Inc. et al.; Proposed Final Judgment and Competitive Impact Statement
2026-14935, United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
The U.S. government says Edwards LifeSciences broke the rules when it bought JC Medical from Genesis MedTech. Edwards must pay $10 million, Genesis pays $2 million, and Edwards has to get approval before buying any company working on special heart valve devices in the U.S. This keeps the market fair and protects competition in heart health tech.
2026-14903, United States, et al. v. OhioHealth Corporation; Proposed Final Judgment and Competitive Impact Statement
The U.S. government and Ohio are taking on OhioHealth Corporation for using sneaky contract rules that stop insurers from offering cheaper health plans. OhioHealth must now remove these rules and promise not to use them again, helping more budget-friendly options reach patients. People have 60 days to share their thoughts before the court makes it official.
2026-14780, Notice Pursuant to the National Cooperative Research and Production Act of 1993-Mobile Satellite Services Association
The Mobile Satellite Services Association (MSSA) just updated its team by adding Creative5 Inc. from Taiwan and saying goodbye to Simnovus Corporation from North Carolina. These changes keep the group’s special legal protections in place, helping members avoid big antitrust lawsuits except for actual damages. If you’re part of MSSA or thinking about joining, keep an eye out—membership is open and updates will keep coming!
Previous / Next Documents
Previous: 2026-14777, Listing Endangered or Threatened Species; 90-Day Finding on a Petition to Revise the Critical Habitat Designation for the North Atlantic Right Whale
NOAA reviewed a request to expand the protected areas for the endangered North Atlantic right whale to include its migratory routes. After checking the science, they decided the current habitat zones are enough and no changes are needed right now. This means no new rules or costs will come from this decision, keeping protections steady for these amazing whales.
Next: 2026-14779, Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.